Holen Sie sich die Stockscreener-App
156.98
2.02%
3.11
Handel nachbörslich:
160.70
3.72
+2.37%
Schlusskurs vom Vortag:
$153.87
Offen:
$152.65
24-Stunden-Volumen:
571.84K
Relative Volume:
1.57
Marktkapitalisierung:
$4.54B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
52.50
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
+6.35%
1M Leistung:
+12.93%
6M Leistung:
-1.73%
1J Leistung:
-21.03%
1-Tages-Spanne:
$151.75
$159.00
1-Wochen-Bereich:
$147.95
$159.00
52-Wochen-Spanne:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
156.98 | 4.45B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
What is the risk reward ratio of investing in Krystal Biotech Inc. stockCapitalize on emerging trends for profits - jammulinksnews.com
What makes Krystal Biotech Inc. stock price move sharplyFree Advanced Stock Screener Access - jammulinksnews.com
What are analysts’ price targets for Krystal Biotech Inc. in the next 12 monthsExceptional market performance - jammulinksnews.com
What drives Krystal Biotech Inc. stock priceGet insider insights into market trends - jammulinksnews.com
Local biotech co-founder named to Forbes 50 Over 50 - The Business Journals
KRYSTAL BIOTECH Earnings Preview: Recent $KRYS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Earnings Outlook For Krystal Biotech - 富途牛牛
How does Krystal Biotech Inc. compare to its industry peersEarnings Report Growth Plan For Smart Trading - jammulinksnews.com
Why is Krystal Biotech Inc. stock attracting strong analyst attentionAI Powered Growth Plan From AI Tools - jammulinksnews.com
Quantitative breakdown of Krystal Biotech Inc. recent moveAlpha Driven Watchlist With Alerts Published - metal.it
How Krystal Biotech Inc. stock performs during market volatilityTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Why Krystal Biotech Inc. stock attracts strong analyst attentionWeekly Chart Analysis With Entry Advice Provided - metal.it
Why We're Not Concerned About Krystal Biotech, Inc.'s (NASDAQ:KRYS) Share Price - 富途牛牛
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Manila Times
Will Krystal Biotech Inc. Recover After Recent DeclineIntraday Trend Analysis for Fast Gains Released - metal.it
Healthcare Stocks: Analysts' Mixed Sentiments on Krystal Biotech and Zimmer Biomet Holdings - AInvest
Krystal Biotech receives regulatory approval to expand to Japan - The Business Journals
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
Krystal Biotech’s Vyjuvek authorised in Japan to treat DEB - World Pharmaceutical Frontiers
What is the dividend policy of Krystal Biotech Inc. stockUnlock your portfolio’s hidden potential - jammulinksnews.com
How volatile is Krystal Biotech Inc. stock compared to the marketFree Stock Chart Pattern Guide - jammulinksnews.com
What catalysts could drive Krystal Biotech Inc. stock higher in 2025Post Market Outlook For Smart Trading - jammulinksnews.com
Is Krystal Biotech Inc. stock overvalued or undervaluedUnlock your portfolio’s full growth potential - jammulinksnews.com
Krystal Biotech Retains 'Buy' Rating with $219 Price Target - AInvest
Krystal Biotech’s Subsidiary Reports Positive Phase 1 Results - The Globe and Mail
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $192 to $240 - 富途牛牛
Krystal Biotech (KRYS) Retains 'Buy' Rating with $219 Price Targ - GuruFocus
What analysts say about Krystal Biotech Inc. stockSuperior returns - PrintWeekIndia
Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential - TipRanks
Krystal Biotech Gains Approval for DEB Treatment in Japan - TipRanks
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech's VYJUVEK Receives Approval in Japan for Dystrophic Epidermolysis Bullosa Treatment from Birth - Quiver Quantitative
Is Krystal Biotech Inc. a good long term investmentFree Predictions - PrintWeekIndia
Revolutionary Genetic Treatment for Rare Skin Disease Gets Historic Japan Approval with Home Use Option - Stock Titan
What risks could impact Krystal Biotech Inc. stock performanceTremendous gains - jammulinksnews.com
Krystal Biotech’s Promising Aesthetic Developments and Positive Phase I Results Justify Buy Rating - TipRanks
Jeune Announces Positive Results and Significant Aesthetic - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Phase 1 Trial Shows 100% Success Rate for Novel Décolleté Wrinkle Treatment | KRYS Stock News - Stock Titan
Krystal Biotech Inc. Stock Analysis and ForecastFree Stock Movement Tracking - jammulinksnews.com
Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities - The Globe and Mail
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):